nach oben

Current Hepatology Reports

Erschienen in:

02.05.2019 | Hepatitis C (H Vargas and S Flamm, Section Editors)

Acute HCV Treatment: What Should We Do in the DAA Era?

verfasst von: Zurabi Lominadze, Robert S. Brown Jr

Erschienen in: Current Hepatology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Acute hepatitis C infection is a growing concern in the USA, especially in light of the opioid epidemic. Prior treatment data consisted of trials in patients receiving interferon-based regimens. There is now emerging evidence regarding the safety and efficacy of direct-acting antivirals for the treatment of acute hepatitis C. This review summarizes the current evidence on the treatment of acute HCV in the DAA era.

Recent Findings

Certain populations, such as people who inject drugs, or HIV-positive men who have sex with men, may benefit from early treatment of acute HCV. As compared with chronic hepatitis C, shorter durations of treatment appear highly effective in acute infection, resulting in reduced viral transmission, as well as potentially reduced overall costs of care related to this disease.

Summary

Further studies are needed to clarify the optimal drug combinations and treatment durations to achieve sustained virologic response in these patients.

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40. https://doi.org/10.3748/wjg.v22.i34.7824.CrossRefPubMedPubMedCentral

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. https://doi.org/10.1002/hep.26141.CrossRefPubMed

The Elimination of Hepatitis C. In: Buckley, GJ and Strom BL, editors. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. 2016. National Academies Press: Washington, DC.

Centers for Disease Control and Prevention. Hepatitis C questions and answers for health professionals. 2018. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1. Accessed 12/1/2018

Surveillance for viral hepatitis – United States, 2016. https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Accessed 12/8/2018.

Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–9. https://doi.org/10.1093/cid/ciu643.CrossRefPubMed

Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.PubMedPubMedCentral

Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012;57(6):1349–60. https://doi.org/10.1016/j.jhep.2012.07.007.CrossRefPubMed

Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23(1):89–93. https://doi.org/10.1097/QAD.0b013e32831940a3.CrossRefPubMedPubMedCentral

10.

Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401–12. https://doi.org/10.1016/j.bpg.2012.09.009.CrossRefPubMed

11.

Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60(6):837–45. https://doi.org/10.1136/gut.2010.217166.CrossRefPubMed

12.

• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41. https://doi.org/10.1111/j.1365-2893.2005.00651.x A landmark systematic review that provides the estimates for spontaneous clearance of acute HCV and factors associated with clearance. CrossRefPubMed

13.

Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–20. https://doi.org/10.1002/hep.26639.CrossRefPubMed

14.

Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198(9):1337–44. https://doi.org/10.1086/592171.CrossRefPubMed

15.

Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol. 2013;59(2):221–8. https://doi.org/10.1016/j.jhep.2013.04.007.CrossRefPubMed

16.

Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59(5):972–7. https://doi.org/10.1016/j.jhep.2013.06.028.CrossRefPubMed

17.

Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013;13(6):497–506. https://doi.org/10.1016/s1473-3099(13)70059-8.CrossRefPubMed

18.

Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, et al. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat. 2015;22(12):1020–32. https://doi.org/10.1111/jvh.12429.CrossRefPubMedPubMedCentral

19.

•• Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2018;67(3):837–46. https://doi.org/10.1002/hep.29611 A study that developed a microsimulation model that showed treating acute HCV is cost-effective, and in some cases, cost-saving compared with deferred treatment. CrossRefPubMedPubMedCentral

20.

AASLD/IDSA. Management of Acute HCV Infection. 2017. https://www.hcvguidelines.org/unique-populations/acute-infection. Accessed 12/8/2018 2018.

21.

Kanzaki H, Takaki A, Yagi T, Ikeda F, Yasunaka T, Koike K, et al. A case of fulminant liver failure associated with hepatitis C virus. Clin J Gastroenterol. 2014;7(2):170–4. https://doi.org/10.1007/s12328-014-0454-x.CrossRefPubMed

22.

Tracy B, Shrestha R, Stein L, Bhasin D, Pollinger H, Rubin RA. Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. Transpl Infect Dis. 2017;19(3). https://doi.org/10.1111/tid.12690.

23.

Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790–802. https://doi.org/10.1111/ajt.14381.CrossRefPubMed

24.

EASL. Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.CrossRef

25.

Basu PP, Shah NJ, Aloysius MM, Brown RS Jr, editors. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir for acute hepatitis C: a RCT: SLAM C study. 25th Annual Conference of APASL. Tokyo: Hepatology International; 2016.

26.

•• Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17(2):215–22. https://doi.org/10.1016/s1473-3099(16)30408-x A trial showing 100% SVR rate for 6 weeks of ledipasvir/sofosbuvir in genotype 1 acute HCV. CrossRefPubMed

27.

• Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2(5):347–53. https://doi.org/10.1016/s2468-1253(17)30003-1 A trial of ledipasvir/sofosbuvir for 6 weeks in patients with genotype 1 or 4 acute HCV coinfected with HIV; sub-optimal SVR rate seen in those with elevated baseline viral load.CrossRefPubMed

28.

•• Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, et al. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat. 2018;25(10):1180–8. https://doi.org/10.1111/jvh.12917 A trial that demonstrated a 97% SVR rate with 8 weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir (with ribavirin) in patients with recent HCV genotype 1 infection. CrossRefPubMed

Titel: Acute HCV Treatment: What Should We Do in the DAA Era?
verfasst von: Zurabi Lominadze
Robert S. Brown Jr
Publikationsdatum: 02.05.2019
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2019
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00463-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Acute HCV Treatment: What Should We Do in the DAA Era?

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

The Role of Hepatic and Splanchnic Lymphatic System in Portal Hypertension and Ascites

State of the Art HCV Treatment in Children

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

Novel Targets and Drug Development in Portal Hypertension

The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?

Management of Fatigue in Primary Biliary Cholangitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin